ENTA logo

Enanta Pharmaceuticals (ENTA) Stock

Profile

Sector:

Healthcare

Industry:

Biotechnology

Country:

United States

IPO:

21 March 2013

Indexes:

Not included

Description:

Enanta Pharmaceuticals, Inc. is an American biotechnology company specializing in the development of small molecule drugs for viral infections and liver diseases. The company was founded in 2004 and is headquartered in Hayward, California, USA. Enanta Pharmaceuticals is conducting clinical development in the following areas: RSV (respiratory syncytial virus). RSV is the most common cause of bronchiolitis (inflammation of the small airways in the lungs) and pneumonia in children under one year of age in the United States. NASH (non-alcoholic steatohepatitis). HBV (hepatitis B virus) - a potentially life-threatening liver infection.

Events Calendar

Earnings

Next earnings date:

N/A

Recent quarterly earnings:

Nov 27, 2024

Recent annual earnings:

Nov 27, 2024
Dividend

Next ex-dividend date:

N/A

Recent ex-dividend date:

N/A
Splits

Next split:

N/A

Recent split:

N/A

Analyst ratings

Recent major analysts updates

10 Oct '24 HC Wainwright & Co.
Buy
09 Oct '24 JMP Securities
Market Outperform
27 Sept '24 JMP Securities
Market Outperform
06 Aug '24 JP Morgan
Underweight
06 Aug '24 HC Wainwright & Co.
Buy
07 May '24 JMP Securities
Market Outperform
07 May '24 HC Wainwright & Co.
Buy
08 Feb '24 JP Morgan
Underweight
22 Nov '23 Oppenheimer
Perform
21 Nov '23 JMP Securities
Outperform

Market Data

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Dividend

Profitability

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Efficiency

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Valuation

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Liquidity

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Cash Flow

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Institutional Ownership

Enanta Pharmaceuticals (ENTA) Reports Q4 Loss, Misses Revenue Estimates
Enanta Pharmaceuticals (ENTA) Reports Q4 Loss, Misses Revenue Estimates
Enanta Pharmaceuticals (ENTA) Reports Q4 Loss, Misses Revenue Estimates
ENTA
zacks.com25 November 2024

Enanta Pharmaceuticals (ENTA) came out with a quarterly loss of $1.36 per share versus the Zacks Consensus Estimate of a loss of $1.16. This compares to loss of $1.33 per share a year ago.

Enanta Pharmaceuticals (ENTA) Surges 5.6%: Is This an Indication of Further Gains?
Enanta Pharmaceuticals (ENTA) Surges 5.6%: Is This an Indication of Further Gains?
Enanta Pharmaceuticals (ENTA) Surges 5.6%: Is This an Indication of Further Gains?
ENTA
zacks.com02 October 2024

Enanta Pharmaceuticals (ENTA) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.

Enanta Pharmaceuticals Announces Positive Topline Results for EDP-323 in a Phase 2a Human Challenge Study of Healthy Adults Infected With Respiratory Syncytial Virus (RSV)
Enanta Pharmaceuticals Announces Positive Topline Results for EDP-323 in a Phase 2a Human Challenge Study of Healthy Adults Infected With Respiratory Syncytial Virus (RSV)
Enanta Pharmaceuticals Announces Positive Topline Results for EDP-323 in a Phase 2a Human Challenge Study of Healthy Adults Infected With Respiratory Syncytial Virus (RSV)
ENTA
businesswire.com26 September 2024

WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals Announces Positive Topline Results for EDP-323 in a Phase 2a Human Challenge Study of Healthy Adults Infected With RSV.

Enanta Pharmaceuticals (ENTA) Reports Q3 Loss, Tops Revenue Estimates
Enanta Pharmaceuticals (ENTA) Reports Q3 Loss, Tops Revenue Estimates
Enanta Pharmaceuticals (ENTA) Reports Q3 Loss, Tops Revenue Estimates
ENTA
zacks.com05 August 2024

Enanta Pharmaceuticals (ENTA) came out with a quarterly loss of $1.07 per share versus the Zacks Consensus Estimate of a loss of $1.49. This compares to loss of $1.86 per share a year ago.

Enanta Pharmaceuticals (ENTA) Soars 6.7%: Is Further Upside Left in the Stock?
Enanta Pharmaceuticals (ENTA) Soars 6.7%: Is Further Upside Left in the Stock?
Enanta Pharmaceuticals (ENTA) Soars 6.7%: Is Further Upside Left in the Stock?
ENTA
zacks.com15 July 2024

Enanta Pharmaceuticals (ENTA) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Enanta Pharmaceuticals (ENTA) Reports Q2 Loss, Tops Revenue Estimates
Enanta Pharmaceuticals (ENTA) Reports Q2 Loss, Tops Revenue Estimates
Enanta Pharmaceuticals (ENTA) Reports Q2 Loss, Tops Revenue Estimates
ENTA
Zacks Investment Research06 May 2024

Enanta Pharmaceuticals (ENTA) reported a quarterly loss of $1.47 per share, which was higher than the Zacks Consensus Estimate of a loss of $1.26 per share. This is an improvement from the loss of $1.79 per share reported in the same quarter last year.

Enanta Pharmaceuticals, Inc. (ENTA) Q1 2024 Earnings Call Transcript
Enanta Pharmaceuticals, Inc. (ENTA) Q1 2024 Earnings Call Transcript
Enanta Pharmaceuticals, Inc. (ENTA) Q1 2024 Earnings Call Transcript
ENTA
Seeking Alpha07 February 2024

Enanta Pharmaceuticals, Inc. (ENTA) Q1 2024 Earnings Call Transcript

Enanta Pharmaceuticals (ENTA) Reports Q1 Loss, Lags Revenue Estimates
Enanta Pharmaceuticals (ENTA) Reports Q1 Loss, Lags Revenue Estimates
Enanta Pharmaceuticals (ENTA) Reports Q1 Loss, Lags Revenue Estimates
ENTA
Zacks Investment Research07 February 2024

Enanta Pharmaceuticals (ENTA) came out with a quarterly loss of $1.58 per share versus the Zacks Consensus Estimate of a loss of $1.18. This compares to loss of $1.39 per share a year ago.

Strength Seen in Enanta Pharmaceuticals (ENTA): Can Its 13.8% Jump Turn into More Strength?
Strength Seen in Enanta Pharmaceuticals (ENTA): Can Its 13.8% Jump Turn into More Strength?
Strength Seen in Enanta Pharmaceuticals (ENTA): Can Its 13.8% Jump Turn into More Strength?
ENTA
Zacks Investment Research05 January 2024

Enanta Pharmaceuticals (ENTA) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

5 Secret Santa Stocks to Pop Surprise Returns
5 Secret Santa Stocks to Pop Surprise Returns
5 Secret Santa Stocks to Pop Surprise Returns
ENTA
Zacks Investment Research19 December 2023

Enanta Pharmaceuticals (ENTA), OneConnect Financial. (OCFT), KNOT Offshore (KNOP), Hippo Holdings (HIPO) and H World Group (HTHT) could surprise investors with big returns this Christmas.

  • 1(current)
  • 2
  • 1(current)
  • 2

FAQ

  • What is the primary business of Enanta Pharmaceuticals?
  • What is the ticker symbol for Enanta Pharmaceuticals?
  • Does Enanta Pharmaceuticals pay dividends?
  • What sector is Enanta Pharmaceuticals in?
  • What industry is Enanta Pharmaceuticals in?
  • What country is Enanta Pharmaceuticals based in?
  • When did Enanta Pharmaceuticals go public?
  • Is Enanta Pharmaceuticals in the S&P 500?
  • Is Enanta Pharmaceuticals in the NASDAQ 100?
  • Is Enanta Pharmaceuticals in the Dow Jones?
  • When was Enanta Pharmaceuticals's last earnings report?
  • When does Enanta Pharmaceuticals report earnings?
  • Should I buy Enanta Pharmaceuticals stock now?

What is the primary business of Enanta Pharmaceuticals?

Enanta Pharmaceuticals, Inc. is an American biotechnology company specializing in the development of small molecule drugs for viral infections and liver diseases. The company was founded in 2004 and is headquartered in Hayward, California, USA. Enanta Pharmaceuticals is conducting clinical development in the following areas: RSV (respiratory syncytial virus). RSV is the most common cause of bronchiolitis (inflammation of the small airways in the lungs) and pneumonia in children under one year of age in the United States. NASH (non-alcoholic steatohepatitis). HBV (hepatitis B virus) - a potentially life-threatening liver infection.

What is the ticker symbol for Enanta Pharmaceuticals?

The ticker symbol for Enanta Pharmaceuticals is NASDAQ:ENTA

Does Enanta Pharmaceuticals pay dividends?

No, Enanta Pharmaceuticals does not pay dividends

What sector is Enanta Pharmaceuticals in?

Enanta Pharmaceuticals is in the Healthcare sector

What industry is Enanta Pharmaceuticals in?

Enanta Pharmaceuticals is in the Biotechnology industry

What country is Enanta Pharmaceuticals based in?

Enanta Pharmaceuticals is headquartered in United States

When did Enanta Pharmaceuticals go public?

Enanta Pharmaceuticals's initial public offering (IPO) was on 21 March 2013

Is Enanta Pharmaceuticals in the S&P 500?

No, Enanta Pharmaceuticals is not included in the S&P 500 index

Is Enanta Pharmaceuticals in the NASDAQ 100?

No, Enanta Pharmaceuticals is not included in the NASDAQ 100 index

Is Enanta Pharmaceuticals in the Dow Jones?

No, Enanta Pharmaceuticals is not included in the Dow Jones index

When was Enanta Pharmaceuticals's last earnings report?

Enanta Pharmaceuticals's most recent earnings report was on 27 November 2024

When does Enanta Pharmaceuticals report earnings?

The date for Enanta Pharmaceuticals's next earnings report has not been announced yet

Should I buy Enanta Pharmaceuticals stock now?

As of today, analysts generally recommend a 'Buy' rating. However, it's important to do your own research and consider your financial situation before making any investment decisions